Editorial
doi: 10.1200/JCO.2009.22.8361.
Epub 2009 Jul 20.
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
- PMID: 19620479
- DOI: 10.1200/JCO.2009.22.8361
Item in Clipboard
Editorial
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
J Clin Oncol.
.
No abstract available
Comment on
-
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620488 Free PMC article.
Similar articles
-
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12. Lancet Oncol. 2011. PMID: 21917518
-
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620488 Free PMC article.
-
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163. BMC Cancer. 2013. PMID: 23537287 Free PMC article.
-
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. doi: 10.5507/bp.2009.002. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009. PMID: 19365520 Review.
-
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Clin Transl Oncol. 2012 Mar;14(3):163-8. doi: 10.1007/s12094-012-0779-1. Clin Transl Oncol. 2012. PMID: 22374418 Review.
Cited by
-
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.South Asian J Cancer. 2018 Apr-Jun;7(2):96-101. doi: 10.4103/sajc.sajc_110_18. South Asian J Cancer. 2018. PMID: 29721472 Free PMC article.
-
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.J Transl Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10. J Transl Med. 2012. PMID: 22240029 Free PMC article.
-
The role of HER-2 in Breast Cancer.J Surg Sci. 2014 Dec;2(1):4-9. J Surg Sci. 2014. PMID: 25679012 Free PMC article. No abstract available.
-
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189395 Free PMC article. Clinical Trial.
-
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.Cancers (Basel). 2022 Apr 24;14(9):2114. doi: 10.3390/cancers14092114. Cancers (Basel). 2022. PMID: 35565244 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
